Health‐related quality of life · people with active UC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · people with active UC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical relapse · Patients with quiescent ulcerative colitis
It is very uncertain whether intervention diet changes clinical relapse at 6 months ‐ Anti‐inflammatory diet (Alberta‐based) compared with control diet (very low certainty).
3 findings from 1 review
RR 1.25 [0.42, 3.7]
1 study · 28 participants
Very low
RR 0.5 [0.15, 1.64]
1 study · 15 participants
Very low
RR 0.83 [0.6, 1.15]
2 studies · 77 participants
Low
Health related quality of life at 12 months ‐ SIBDQ ‐ Carrageenan‐free diet · Patients with quiescent ulcerative colitis
1 finding from 1 review
Adverse events · Patients with quiescent ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Induction of remission (timeframe not reported) ‐ Symptoms‐guided diet · Patients with active Crohn's disease
It is very uncertain whether intervention diet changes induction of remission (timeframe not reported) ‐ Symptoms‐guided diet compared with control diet (very low certainty).
1 finding from 1 review
Health‐related quality of life (timeframe not reported) ‐ IBDQ ‐ Symptoms‐guided diet · Patients with active Crohn's disease
1 finding from 1 review
QoL · Patients with active Crohn's disease
1 finding from 1 review
Adverse events · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
OutcomesAnalysis 1.4 · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Failure to achieve clinical remission · Patients with active Crohn's disease
The intervention leads to lower failure to achieve clinical remission (high certainty).
1 finding from 1 review
Intervention not reported
Failure to achieve clinical response (70‐point response) · Patients with active Crohn's disease
The intervention leads to lower failure to achieve clinical response (70‐point response) (high certainty).
1 finding from 1 review
Intervention not reported
Failure to achieve clinical response (100‐point response) · Patients with active Crohn's disease
The intervention leads to lower failure to achieve clinical response (100‐point response) (high certainty).
1 finding from 1 review
Intervention not reported
Endoscopic response · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Quality of life (QoL) Inflammatory Bowel Disease Questionnaire (IBDQ) (scale: 32 to 224; higher score = better QoL) · Patients with active Crohn's disease
1 finding from 1 review
Intervention not reported
Adverse events · Patients with active Crohn's disease
The intervention showed no clear difference in adverse events (moderate certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events · Patients with active Crohn's disease
The intervention showed no clear difference in serious adverse events (low certainty).
1 finding from 1 review
Intervention not reported
Withdrawals due to adverse events · Patients with active Crohn's disease
The intervention showed no clear difference in withdrawals due to adverse events (low certainty).
1 finding from 1 review
Clinical remission · Patients with active Crohn's disease
Certolizumab pegol probably leads to higher clinical remission compared with placebo (moderate certainty).
1 finding from 1 review
Clinical response · Patients with active Crohn's disease
Certolizumab pegol probably leads to higher clinical response compared with placebo (moderate certainty).
1 finding from 1 review